S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

CorMedix Stock Price, News & Analysis (NASDAQ:CRMD)

$3.56
-0.01 (-0.28%)
(As of 12/8/2023 ET)
Compare
Today's Range
$3.51
$3.74
50-Day Range
$3.00
$4.01
52-Week Range
$2.57
$6.09
Volume
933,766 shs
Average Volume
568,008 shs
Market Capitalization
$195.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.25

CorMedix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
300.3% Upside
$14.25 Price Target
Short Interest
Bearish
12.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.80) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

639th out of 954 stocks

Pharmaceutical Preparations Industry

235th out of 362 stocks


CRMD stock logo

About CorMedix Stock (NASDAQ:CRMD)

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CRMD Stock Price History

CRMD Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Why CorMedix Stock Popped Wednesday
U.S. FDA approves CorMedix's antimicrobial drug
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
ARCT, MNTS and SNBR are among after hour movers
CorMedix GAAP EPS of -$0.17 beats by $0.04
CorMedix Q3 2023 Earnings Preview
Here's what Wall Street expects from Cormedix's earnings
Cormedix Inc CRMD
RBC Capital Sticks to Their Buy Rating for Cormedix (CRMD)
See More Headlines
Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRMD
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.25
High Stock Price Target
$19.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+300.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-29,700,000.00
Pretax Margin
-132,646.69%

Debt

Sales & Book Value

Annual Sales
$29,702.00
Book Value
$1.33 per share

Miscellaneous

Free Float
52,291,000
Market Cap
$195.13 million
Optionable
Optionable
Beta
1.86
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Joseph Todisco MBA (Age 47)
    CEO & Director
    Comp: $927.62k
  • Dr. Matthew T. David M.D. (Age 45)
    Executive VP & CFO
    Comp: $830.64k
  • Dr. Phoebe Mounts Esq. (Age 72)
    Ph.D., EVP, General Counsel, Head of Regulatory, Compliance & Legal and Secretary
    Comp: $582.22k
  • Ms. Elizabeth Masson-Hurlburt B.A. (Age 44)
    Executive VP and Head of Clinical & Medical Affairs
    Comp: $538.91k
  • Donna Ucci
    Senior VP & Head of Global Quality
  • Dr. Tushar Mukherjee
    Senior VP & Head of Technical Operations
  • Ms. Erin Mistry (Age 41)
    Executive VP & Chief Commercial Officer














CRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CorMedix stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRMD shares.
View CRMD analyst ratings
or view top-rated stocks.

What is CorMedix's stock price target for 2024?

4 brokerages have issued twelve-month price objectives for CorMedix's stock. Their CRMD share price targets range from $10.00 to $19.00. On average, they anticipate the company's stock price to reach $14.25 in the next year. This suggests a possible upside of 300.3% from the stock's current price.
View analysts price targets for CRMD
or view top-rated stocks among Wall Street analysts.

How have CRMD shares performed in 2023?

CorMedix's stock was trading at $4.22 at the start of the year. Since then, CRMD shares have decreased by 15.6% and is now trading at $3.56.
View the best growth stocks for 2023 here
.

When is CorMedix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CRMD earnings forecast
.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04.

What ETF holds CorMedix's stock ?

ETFMG Treatments Testing and Advancements ETF holds 12,811 shares of CRMD stock, representing 0.39% of its portfolio.

When did CorMedix's stock split?

CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL).

Who are CorMedix's major shareholders?

CorMedix's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.82%), Bank of New York Mellon Corp (0.28%), Charles Schwab Investment Management Inc. (0.26%), Invesco Ltd. (0.10%), Rhumbline Advisers (0.10%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan.
View institutional ownership trends
.

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRMD) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -